Nutex Health Inc.: Form 10-Q for the period ended Sep 30, 2014
Filed with the SEC on Nov 12, 2014 and accepted by EDGAR at Nov 12, 2014, 12:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-07-01 to 2014-09-30 | $269.2k | us-gaap:SalesRevenueNet |
| Revenue | 9 months2014-01-01 to 2014-09-30 | $819.8k | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2014-07-01 to 2014-09-30 | $115.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2014-01-01 to 2014-09-30 | $341.8k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-07-01 to 2014-09-30 | $154.0k | us-gaap:GrossProfit |
| Gross profit | 9 months2014-01-01 to 2014-09-30 | $478.0k | us-gaap:GrossProfit |
| Operating income | 3 months2014-07-01 to 2014-09-30 | −$184.3k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2014-01-01 to 2014-09-30 | −$520.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-07-01 to 2014-09-30 | −$1.4k | us-gaap:InterestExpense |
| Interest expense | 9 months2014-01-01 to 2014-09-30 | −$8.4k | us-gaap:InterestExpense |
| Net income | 3 months2014-07-01 to 2014-09-30 | −$185.8k | us-gaap:NetIncomeLoss |
| Net income | 9 months2014-01-01 to 2014-09-30 | −$422.6k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-07-01 to 2014-09-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2014-01-01 to 2014-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2014-07-01 to 2014-09-30 | 26,709,056 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2014-01-01 to 2014-09-30 | 25,737,023 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2014-01-01 to 2014-09-30 | $364.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2014-01-01 to 2014-09-30 | −$2.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-09-30 | $332.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-09-30 | $474.5k | us-gaap:AssetsCurrent |
| Total assets | At period end2014-09-30 | $496.2k | us-gaap:Assets |
| Current liabilities | At period end2014-09-30 | $292.6k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2014-09-30 | $203.7k | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001211524-14-000116. Last ingested by Listed: Nov 14, 2026, 12:46 ET. Listed shows no prices and gives no investment advice.